Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.

ABSTRACT:

Background

Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive value for long-term clinical outcomes remains unclear.

Objective

We measured NfL from a phase 3 trial in relapsing-remitting MS and investigated its association with outcomes after 8 and 15 years.

Methods

NfL concentrations were measured by single molecule array assay in cerebrospinal fluid (CSF) from MS patients (n = 235) in a 2-year randomized clinical trial (RCT) of intramuscular interferon β-1a, and in serum (n = 164) from the extension study.

Results

Year 2 CSF and Year 3 serum NfL were associated with brain parenchymal fraction (BPF) change over 8 years (p < 0.0001, r = -0.4

SUBMITTER: Kuhle J 

PROVIDER: S-EPMC7604552 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature